Cingulate Therapeutics
Major Drugs - Westwood, Kansas, US
Cingulate Therapeutics Employees
Cingulate Therapeutics Senior Management
Cingulate Therapeutics Details
Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 (Dexmethylphenidate) and CTX-1302 (Dextroamphetamine), via the accelerated 505 (b)(2) regulatory pathway for the treatment of ADHD seeking indications for all patient segments: children, adolescents and adults. The Company has completed its proof of concept trial in human subjects to validate the novel Target Product Profiles for both CTX-1301 and CTX-1302. After a planned submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2018, Cingulate intends to implement the full clinical plan for both CTX-1301 and CTX-1302 in 2018.
Cingulate Therapeutics Technologies
Load Balancers
Apache
Fonts
Google Font API
Other
Mobile Friendly
Search Marketing
Adobe Marketing Cloud
Analytics and Tracking
Google Analytics